Evaluation of different platforms for the detection of anti-SARS coronavirus-2 antibodies, Thailand

• Published in: BMC infectious diseases Vol. 21; no. 1; pp. 1213 - 9
• Main Authors: Lerdsamran, Hatairat, Mungaomklang, Anek, Iamsirithaworn, Sopon, Prasertsopon, Jarunee, Prasert, Kriengkrai, Intalapaporn, Poj, Siriyakorn, Nirada, Wiriyarat, Witthawat, Thinpan, Nattakan, Sawadpongpan, Suteema, Sirikhetkon, Somrak, Mongkalangoon, Noparat, Petto, Suwanna, Puthavathana, Pilaipan
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 06.12.2021; BioMed Central; BMC
• Subjects: Antibodies; Antibody detection; Antigens; Architects; Assaying; Chemiluminescence assay; Coronaviruses; COVID-19; Disease control; ELISA; Enzyme-linked immunosorbent assay; Epidemics; Immunofluorescence; Immunoglobulin G; Immunology; Infections; Informed consent; Laboratories; Microneutralization assay; Performance evaluation; Proteins; Public health; Respiratory diseases; SARS-coronavirus-2; Sensitivity analysis; Seroepidemiology; Serology; Severe acute respiratory syndrome coronavirus 2; Testing; Travellers; Viral antibodies; Viral diseases; Viruses; Thailand; Beijing China; United States > US; China; Antibody detection; Microneutralization assay; SARS-coronavirus-2; Chemiluminescence assay; ELISA

Antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) help determine previous infection in individuals, regardless of whether they are asymptomatic or symptomatic. The detection of antibodies serves several purposes, including supporting other assays for disease diagnosis,...